Cybin Inc. (New York Stock Exchange Arca:CYBN)
| Market Cap | $413.02M-15.8% |
| Revenue (ttm) | $0 |
| Net Income | -$92.91M+24.9% |
| EPS | -$4.17-23.0% |
| Shares Out | 49.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 716,528 |
| Open | $8.28 |
| Previous Close | $8.18 |
| Day's Range | $8.14 - $8.38 |
| 52-Week Range | $4.81 - $10.72 |
| Beta | 0.79 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | n/a |
About CYBN
Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.
Cybin Inc. Stock Analysis — InsiderScore
Cybin Inc. scored higher than 87% of companies evaluated by InsiderBuying, and ranked 12th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Cybin Inc. bought $9.67 million of stock across 9 purchases in the last 90 days, the largest of them $1.35 million.
The average purchase added about 19% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
When insiders bought and sold
1 year · open-market trades only$CYBN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CYBN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CYBN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CYBN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CYBN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CYBN from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from CYBN’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-5.9 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
